CNS Specific Antisense Oligonucleotide Market to 2027 - Global Analysis and Forecasts By Indication ( Hereditary Transthyretin Amyloidosis (hATTR)/ Polyneuropathy, Spinal Muscular Atrophy, Huntington's Disease ); Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy )
Report Code: TIPRE00003408 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
Antisense oligonucleotides are manufactured as they have the potential of being used as therapeutic agents. The Antisense oligonucleotides block the disease processes by altering the metabolic pathway of a particular protein. This is achieved by the binding the antisense oligonucleotide to the mRNA from which that protein is normally synthesized. Binding of the antisense oligonucleotide blocks the ability of ribosomes to move along the messenger RNA preventing synthesis of the protein. CNS specific antisense oligonucleotide is used for treatment of neurodegenerative disorders and associated rare diseases.
MARKET DYNAMICS
The CNS Specific Antisense Oligonucleotide market is anticipated to grow in the forecast period owing to driving factors such as growing prevalence of neurodegenerative disorders and associated rare diseases, increasing launch of antisense drugs, rising research and development activities for antisense oligonucleotide. The market is subject to various stringent laws and regulations that deal with patenting, testing, safety, efficacy and marketing, this eventually hampers the market growth.
MARKET SCOPE
The "Global CNS Specific Antisense Oligonucleotide Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of CNS specific antisense oligonucleotide market with detailed market segmentation by indication, distribution channel and geography. The global CNS specific antisense oligonucleotide market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading CNS specific antisense oligonucleotide market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global CNS specific antisense oligonucleotide market is segmented on the basis of indication and distribution channel. Based on indication, the market is segmented as hereditary transthyretin amyloidosis (hATTR)/ polyneuropathy, spinal muscular atrophy and Huntington's disease. The CNS Specific Antisense Oligonucleotide market, based on distribution channel is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global CNS Specific Antisense Oligonucleotide market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The CNS Specific Antisense Oligonucleotide market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting CNS Specific Antisense Oligonucleotide market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the CNS Specific Antisense Oligonucleotide market in these regions.
MARKET PLAYERS
The reports cover key developments in the CNS Specific Antisense Oligonucleotide market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from CNS Specific Antisense Oligonucleotide market are anticipated to lucrative growth opportunities in the future with the rising demand for CNS Specific Antisense Oligonucleotide market in the global market. Below mentioned is the list of few companies engaged in the CNS Specific Antisense Oligonucleotide market.
The report also includes the profiles of key CNS Specific Antisense Oligonucleotide market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
• Alnylam Pharmaceuticals Inc.
• Sarepta Therapeutics Inc.
• Biogen Inc.
• Ionis Pharmaceuticals Inc.
• Wave Life Sciences Ltd.
• Stroke Therapeutic Inc.
• Dynacure
• ProQR Therapeutics N.V.
• Q-STATE BIOSCIENCES, INC.
• GlaxoSmithKline plc
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Antisense oligonucleotides are manufactured as they have the potential of being used as therapeutic agents. The Antisense oligonucleotides block the disease processes by altering the metabolic pathway of a particular protein. This is achieved by the binding the antisense oligonucleotide to the mRNA from which that protein is normally synthesized. Binding of the antisense oligonucleotide blocks the ability of ribosomes to move along the messenger RNA preventing synthesis of the protein. CNS specific antisense oligonucleotide is used for treatment of neurodegenerative disorders and associated rare diseases.
MARKET DYNAMICS
The CNS Specific Antisense Oligonucleotide market is anticipated to grow in the forecast period owing to driving factors such as growing prevalence of neurodegenerative disorders and associated rare diseases, increasing launch of antisense drugs, rising research and development activities for antisense oligonucleotide. The market is subject to various stringent laws and regulations that deal with patenting, testing, safety, efficacy and marketing, this eventually hampers the market growth.
MARKET SCOPE
The "Global CNS Specific Antisense Oligonucleotide Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of CNS specific antisense oligonucleotide market with detailed market segmentation by indication, distribution channel and geography. The global CNS specific antisense oligonucleotide market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading CNS specific antisense oligonucleotide market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global CNS specific antisense oligonucleotide market is segmented on the basis of indication and distribution channel. Based on indication, the market is segmented as hereditary transthyretin amyloidosis (hATTR)/ polyneuropathy, spinal muscular atrophy and Huntington's disease. The CNS Specific Antisense Oligonucleotide market, based on distribution channel is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global CNS Specific Antisense Oligonucleotide market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The CNS Specific Antisense Oligonucleotide market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting CNS Specific Antisense Oligonucleotide market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the CNS Specific Antisense Oligonucleotide market in these regions.
The reports cover key developments in the CNS Specific Antisense Oligonucleotide market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from CNS Specific Antisense Oligonucleotide market are anticipated to lucrative growth opportunities in the future with the rising demand for CNS Specific Antisense Oligonucleotide market in the global market. Below mentioned is the list of few companies engaged in the CNS Specific Antisense Oligonucleotide market.
The report also includes the profiles of key CNS Specific Antisense Oligonucleotide market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
• Alnylam Pharmaceuticals Inc.
• Sarepta Therapeutics Inc.
• Biogen Inc.
• Ionis Pharmaceuticals Inc.
• Wave Life Sciences Ltd.
• Stroke Therapeutic Inc.
• Dynacure
• ProQR Therapeutics N.V.
• Q-STATE BIOSCIENCES, INC.
• GlaxoSmithKline plc
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 CNS Specific Antisense Oligonucleotide Market - By Indication
1.3.2 CNS Specific Antisense Oligonucleotide Market - By Distribution Channel
1.3.3 CNS Specific Antisense Oligonucleotide Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.3.1 North America - Pest Analysis
4.3.2 Europe - Pest Analysis
4.3.3 Asia-Pacific - Pest Analysis
4.3.4 Middle East and Africa - Pest Analysis
4.3.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET - GLOBAL MARKET ANALYSIS
6.1. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE - GLOBAL MARKET OVERVIEW
6.2. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET - REVENUE AND FORECASTS TO 2027 - INDICATION
7.1. OVERVIEW
7.2. INDICATION MARKET FORECASTS AND ANALYSIS
7.3. HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR)/ POLYNEUROPATHY
7.3.1. Overview
7.3.2. Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy Market Forecast and Analysis
7.4. SPINAL MUSCULAR ATROPHY
7.4.1. Overview
7.4.2. Spinal Muscular Atrophy Market Forecast and Analysis
7.5. HUNTINGTON'S DISEASE
7.5.1. Overview
7.5.2. Huntington's Disease Market Forecast and Analysis
8. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACY
8.3.1. Overview
8.3.2. Hospital Pharmacy Market Forecast and Analysis
8.4. RETAIL PHARMACY
8.4.1. Overview
8.4.2. Retail Pharmacy Market Forecast and Analysis
8.5. ONLINE PHARMACY
8.5.1. Overview
8.5.2. Online Pharmacy Market Forecast and Analysis
9. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America CNS Specific Antisense Oligonucleotide Market Overview
9.1.2 North America CNS Specific Antisense Oligonucleotide Market Forecasts and Analysis
9.1.3 North America Market Forecasts and Analysis - By Indication
9.1.4 North America Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Market Forecasts and Analysis - By Countries
9.1.5.1 United States Market
9.1.5.1.1 United States Market by Indication
9.1.5.1.2 United States Market by Distribution Channel
9.1.5.2 Canada Market
9.1.5.2.1 Canada Market by Indication
9.1.5.2.2 Canada Market by Distribution Channel
9.1.5.3 Mexico Market
9.1.5.3.1 Mexico Market by Indication
9.1.5.3.2 Mexico Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe CNS Specific Antisense Oligonucleotide Market Overview
9.2.2 Europe CNS Specific Antisense Oligonucleotide Market Forecasts and Analysis
9.2.3 Europe Market Forecasts and Analysis - By Indication
9.2.4 Europe Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Market
9.2.5.1.1 Germany Market by Indication
9.2.5.1.2 Germany Market by Distribution Channel
9.2.5.2 France Market
9.2.5.2.1 France Market by Indication
9.2.5.2.2 France Market by Distribution Channel
9.2.5.3 Italy Market
9.2.5.3.1 Italy Market by Indication
9.2.5.3.2 Italy Market by Distribution Channel
9.2.5.4 Spain Market
9.2.5.4.1 Spain Market by Indication
9.2.5.4.2 Spain Market by Distribution Channel
9.2.5.5 United Kingdom Market
9.2.5.5.1 United Kingdom Market by Indication
9.2.5.5.2 United Kingdom Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific CNS Specific Antisense Oligonucleotide Market Overview
9.3.2 Asia-Pacific CNS Specific Antisense Oligonucleotide Market Forecasts and Analysis
9.3.3 Asia-Pacific Market Forecasts and Analysis - By Indication
9.3.4 Asia-Pacific Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Market
9.3.5.1.1 Australia Market by Indication
9.3.5.1.2 Australia Market by Distribution Channel
9.3.5.2 China Market
9.3.5.2.1 China Market by Indication
9.3.5.2.2 China Market by Distribution Channel
9.3.5.3 India Market
9.3.5.3.1 India Market by Indication
9.3.5.3.2 India Market by Distribution Channel
9.3.5.4 Japan Market
9.3.5.4.1 Japan Market by Indication
9.3.5.4.2 Japan Market by Distribution Channel
9.3.5.5 South Korea Market
9.3.5.5.1 South Korea Market by Indication
9.3.5.5.2 South Korea Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa CNS Specific Antisense Oligonucleotide Market Overview
9.4.2 Middle East and Africa CNS Specific Antisense Oligonucleotide Market Forecasts and Analysis
9.4.3 Middle East and Africa Market Forecasts and Analysis - By Indication
9.4.4 Middle East and Africa Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Market
9.4.5.1.1 South Africa Market by Indication
9.4.5.1.2 South Africa Market by Distribution Channel
9.4.5.2 Saudi Arabia Market
9.4.5.2.1 Saudi Arabia Market by Indication
9.4.5.2.2 Saudi Arabia Market by Distribution Channel
9.4.5.3 U.A.E Market
9.4.5.3.1 U.A.E Market by Indication
9.4.5.3.2 U.A.E Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America CNS Specific Antisense Oligonucleotide Market Overview
9.5.2 South and Central America CNS Specific Antisense Oligonucleotide Market Forecasts and Analysis
9.5.3 South and Central America Market Forecasts and Analysis - By Indication
9.5.4 South and Central America Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Market
9.5.5.1.1 Brazil Market by Indication
9.5.5.1.2 Brazil Market by Distribution Channel
9.5.5.2 Argentina Market
9.5.5.2.1 Argentina Market by Indication
9.5.5.2.2 Argentina Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET, KEY COMPANY PROFILES
11.1. ALNYLAM PHARMACEUTICALS INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. SAREPTA THERAPEUTICS INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BIOGEN INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. IONIS PHARMACEUTICALS INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. WAVE LIFE SCIENCES LTD.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. STROKE THERAPEUTIC INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. DYNACURE
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PROQR THERAPEUTICS N.V.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. Q-STATE BIOSCIENCES, INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 CNS Specific Antisense Oligonucleotide Market - By Indication
1.3.2 CNS Specific Antisense Oligonucleotide Market - By Distribution Channel
1.3.3 CNS Specific Antisense Oligonucleotide Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.3.1 North America - Pest Analysis
4.3.2 Europe - Pest Analysis
4.3.3 Asia-Pacific - Pest Analysis
4.3.4 Middle East and Africa - Pest Analysis
4.3.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET - GLOBAL MARKET ANALYSIS
6.1. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE - GLOBAL MARKET OVERVIEW
6.2. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET - REVENUE AND FORECASTS TO 2027 - INDICATION
7.1. OVERVIEW
7.2. INDICATION MARKET FORECASTS AND ANALYSIS
7.3. HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR)/ POLYNEUROPATHY
7.3.1. Overview
7.3.2. Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy Market Forecast and Analysis
7.4. SPINAL MUSCULAR ATROPHY
7.4.1. Overview
7.4.2. Spinal Muscular Atrophy Market Forecast and Analysis
7.5. HUNTINGTON'S DISEASE
7.5.1. Overview
7.5.2. Huntington's Disease Market Forecast and Analysis
8. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACY
8.3.1. Overview
8.3.2. Hospital Pharmacy Market Forecast and Analysis
8.4. RETAIL PHARMACY
8.4.1. Overview
8.4.2. Retail Pharmacy Market Forecast and Analysis
8.5. ONLINE PHARMACY
8.5.1. Overview
8.5.2. Online Pharmacy Market Forecast and Analysis
9. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America CNS Specific Antisense Oligonucleotide Market Overview
9.1.2 North America CNS Specific Antisense Oligonucleotide Market Forecasts and Analysis
9.1.3 North America Market Forecasts and Analysis - By Indication
9.1.4 North America Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Market Forecasts and Analysis - By Countries
9.1.5.1 United States Market
9.1.5.1.1 United States Market by Indication
9.1.5.1.2 United States Market by Distribution Channel
9.1.5.2 Canada Market
9.1.5.2.1 Canada Market by Indication
9.1.5.2.2 Canada Market by Distribution Channel
9.1.5.3 Mexico Market
9.1.5.3.1 Mexico Market by Indication
9.1.5.3.2 Mexico Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe CNS Specific Antisense Oligonucleotide Market Overview
9.2.2 Europe CNS Specific Antisense Oligonucleotide Market Forecasts and Analysis
9.2.3 Europe Market Forecasts and Analysis - By Indication
9.2.4 Europe Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Market
9.2.5.1.1 Germany Market by Indication
9.2.5.1.2 Germany Market by Distribution Channel
9.2.5.2 France Market
9.2.5.2.1 France Market by Indication
9.2.5.2.2 France Market by Distribution Channel
9.2.5.3 Italy Market
9.2.5.3.1 Italy Market by Indication
9.2.5.3.2 Italy Market by Distribution Channel
9.2.5.4 Spain Market
9.2.5.4.1 Spain Market by Indication
9.2.5.4.2 Spain Market by Distribution Channel
9.2.5.5 United Kingdom Market
9.2.5.5.1 United Kingdom Market by Indication
9.2.5.5.2 United Kingdom Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific CNS Specific Antisense Oligonucleotide Market Overview
9.3.2 Asia-Pacific CNS Specific Antisense Oligonucleotide Market Forecasts and Analysis
9.3.3 Asia-Pacific Market Forecasts and Analysis - By Indication
9.3.4 Asia-Pacific Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Market
9.3.5.1.1 Australia Market by Indication
9.3.5.1.2 Australia Market by Distribution Channel
9.3.5.2 China Market
9.3.5.2.1 China Market by Indication
9.3.5.2.2 China Market by Distribution Channel
9.3.5.3 India Market
9.3.5.3.1 India Market by Indication
9.3.5.3.2 India Market by Distribution Channel
9.3.5.4 Japan Market
9.3.5.4.1 Japan Market by Indication
9.3.5.4.2 Japan Market by Distribution Channel
9.3.5.5 South Korea Market
9.3.5.5.1 South Korea Market by Indication
9.3.5.5.2 South Korea Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa CNS Specific Antisense Oligonucleotide Market Overview
9.4.2 Middle East and Africa CNS Specific Antisense Oligonucleotide Market Forecasts and Analysis
9.4.3 Middle East and Africa Market Forecasts and Analysis - By Indication
9.4.4 Middle East and Africa Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Market
9.4.5.1.1 South Africa Market by Indication
9.4.5.1.2 South Africa Market by Distribution Channel
9.4.5.2 Saudi Arabia Market
9.4.5.2.1 Saudi Arabia Market by Indication
9.4.5.2.2 Saudi Arabia Market by Distribution Channel
9.4.5.3 U.A.E Market
9.4.5.3.1 U.A.E Market by Indication
9.4.5.3.2 U.A.E Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America CNS Specific Antisense Oligonucleotide Market Overview
9.5.2 South and Central America CNS Specific Antisense Oligonucleotide Market Forecasts and Analysis
9.5.3 South and Central America Market Forecasts and Analysis - By Indication
9.5.4 South and Central America Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Market
9.5.5.1.1 Brazil Market by Indication
9.5.5.1.2 Brazil Market by Distribution Channel
9.5.5.2 Argentina Market
9.5.5.2.1 Argentina Market by Indication
9.5.5.2.2 Argentina Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET, KEY COMPANY PROFILES
11.1. ALNYLAM PHARMACEUTICALS INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. SAREPTA THERAPEUTICS INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BIOGEN INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. IONIS PHARMACEUTICALS INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. WAVE LIFE SCIENCES LTD.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. STROKE THERAPEUTIC INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. DYNACURE
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PROQR THERAPEUTICS N.V.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. Q-STATE BIOSCIENCES, INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies
1. Alnylam Pharmaceuticals Inc.
2. Sarepta Therapeutics Inc.
3. Biogen Inc.
4. Ionis Pharmaceuticals Inc.
5. Wave Life Sciences Ltd.
6. Stroke Therapeutic Inc.
7. Dynacure
8. ProQR Therapeutics N.V.
9. Q-STATE BIOSCIENCES, INC.
10. GlaxoSmithKline plc
1. Alnylam Pharmaceuticals Inc.
2. Sarepta Therapeutics Inc.
3. Biogen Inc.
4. Ionis Pharmaceuticals Inc.
5. Wave Life Sciences Ltd.
6. Stroke Therapeutic Inc.
7. Dynacure
8. ProQR Therapeutics N.V.
9. Q-STATE BIOSCIENCES, INC.
10. GlaxoSmithKline plc